Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Capital Expenditures of $5000.0 for Q3 2025, down 80.0% year-over-year from $25000.0 in Q3 2024, and down 89.13% quarter-over-quarter from $46000.0 in Q2 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $5000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures fell 80.0% year-over-year to $5000.0; the TTM figure through Sep 2025 stood at $106000.0 (up 26.19% YoY), while the FY2024 annual figure was $105000.0, down 4.55% from the prior year.
- Capital Expenditures for Q3 2025 stood at $5000.0, down from $46000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.0 million in Q2 2021, with the low at -$46000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $25000.0 (2024), against an average of $89105.3.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures surged 2727.78% in 2021, then sank 120.54% in 2022.
- Dianthus Therapeutics' Capital Expenditures stood at $15000.0 in 2021, then soared by 93.33% to $29000.0 in 2022, then tumbled by 65.52% to $10000.0 in 2023, then soared by 210.0% to $31000.0 in 2024, then slumped by 83.87% to $5000.0 in 2025.
- Business Quant data shows DNTH's Capital Expenditures at $5000.0 in Q3 2025, $46000.0 in Q2 2025, and $24000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 10,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 21,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | -46,000.00 |
| Jun 30, 2022 | 129,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Dec 31, 2021 | 15,000.00 |
| Sep 30, 2021 | 224,000.00 |
| Jun 30, 2021 | 1.02 Mn |
| Mar 31, 2021 | 7,000.00 |
| Dec 31, 2020 | 213,000.00 |